NovoCure (NVCR) shares soared higher today as the company gave an update on a phase 3 trial of a treatment for non-small cell lung cancer.
More from Investing
We didn't see much wild rotation, but the Russell 2000 did outperform, and the negative action could prove good from a technical standpoint.
In fact, the charts of APD are bullish. Here's what they say.
The shares have been in a rally phase since early November.